US Patent 9925269 Phospholipid ether analogs as cancer-targeting drug vehicles
Patent 9925269 was granted and assigned to Cellectar on March, 2018 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
November 6, 2015
0
Date of Patent
March 27, 2018
0
Patent Applicant
Patent Application Number
14934203
0
Patent Inventor Names
Jamey P. Weichert
0
Kevin Kozak
0
Joseph Grudzinski
0
Nathan Stehle
0
Marc Longino
0
Anatoly Pinchuk
0
Benjamin Titz
0
Chorom Pak
0
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 9925269 Phospholipid ether analogs as cancer-targeting drug vehicles
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.